The DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.
Lapatinib (Tykerb, GW572016) Reverses Multidrug Resistance in Cancer Cells by Inhibiting the Activity of ATP-Binding Cassette Subfamily B Member 1 and G Member 2
Open accessPublished version of a preprint
Abstract
Lapatinib is active at the ATP-binding site of tyrosine kinases that are associated with the human epidermal growth factor receptor (Her-1 or ErbB1) and Her-2. It is conceivable that lapatinib may inhibit the function of ATP-binding cassette (ABC) transporters by binding to their ATP-binding sites. The aim of this study was to investigate the ability of lapatinib to reverse tumor multidrug resistance (MDR) due to overexpression of ABC subfamily B member 1 (ABCB1) and ABC subfamily G member 2 (ABCG2) transporters. Our results showed that lapatinib significantly enhanced the sensitivity to ABCB1 or ABCG2 substrates in cells expressing these transporters, although a small synergetic effect was observed in combining lapatinib and conventional chemotherapeutic agents in parental sensitive MCF-7 or S1 cells. Lapatinib alone, however, did not significantly alter the sensitivity of non-ABCB1 or non-ABCG2 substrates in sensitive and resistant cells. Additionally, lapatinib significantly increased the accumulation of doxorubicin or mitoxantrone in ABCB1- or ABCG2-overexpressing cells and inhibited the transport of methotrexate and E217βG by ABCG2. Furthermore, lapatinib stimulated the ATPase activity of both ABCB1 and ABCG2 and inhibited the photolabeling of ABCB1 or ABCG2 with [125I]iodoarylazidoprazosin in a concentration-dependent manner. However, lapatinib did not affect the expression of these transporters at mRNA or protein levels. Importantly, lapatinib also strongly enhanced the effect of paclitaxel on the inhibition of growth of the ABCB1-overexpressing KBv200 cell xenografts in nude mice. Overall, we conclude that lapatinib reverses ABCB1- and ABCG2-mediated MDR by directly inhibiting their transport function. These findings may be useful for cancer combinational therapy with lapatinib in the clinic. [Cancer Res 2008;68(19):7905–14]
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The ErbB receptor inhibitor lapatinib is an U.S. Food and Drug Administration (FDA) approved drug for the treatment of several HER2 driven cancers and has been shown to also directly inhibit the drug efflux activity of MDR1, both in cancer cells and in in vivo tumor models (36).”
From The drug efflux pump MDR1 promotes intrinsic and acquired resistance to PROTACs in cancer cells (2022) · cites this paper as [36]
In the citing paper
“lapatinib has previously been shown to be a competitive inhibitor of MDR1 both in vitro and in vivo (36)”
From The drug efflux pump MDR1 promotes intrinsic and acquired resistance to PROTACs in cancer cells (2022) · cites this paper as [36]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lapatinib plus Capecitabine for HER2-Positive Advanced Breast Cancer
Geyer, C. E., Forster, J. K., Lindquist, D. L., Chan, S. Y. T., Romieu, C. G., Pieńkowski, T., Jagiełło-Gruszfeld, A., Crown, J. P., Chan, A., Kaufman, B., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa064320 · Cited by 3,458
Epidermal growth factor receptor (EGFR) signaling in cancer
Normanno, N., Luca, A. D., Bianco, C., Strizzi, L., Mancino, M., Maiello, M. R., Carotenuto, A., Feo, G. D., Caponigro, F., & Salomon, D. S. (2005) · Gene · doi:10.1016/j.gene.2005.10.018 · Cited by 2,088
The Human ATP-Binding Cassette (ABC) Transporter SuperfamilyPreprint
Dean, M. C., Rzhetsky, A., & Allikmets, R. L. (2001) · Genome Research · doi:10.1101/gr.184901 · Cited by 1,820
P-glycoprotein: from genomics to mechanism
Ambudkar, S. V., Kimchi‐Sarfaty, C., Sauna, Z. E., & Gottesman, M. M. (2003) · Oncogene · doi:10.1038/sj.onc.1206948 · Cited by 1,092
Self-citationMultidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2)
Doyle, L. A., & Ross, D. D. (2003) · Oncogene · doi:10.1038/sj.onc.1206938 · Cited by 1,056
Burris, H. A., Hurwitz, H. I., Dees, E. C., Dowlati, A., Blackwell, K., O’Neil, B. H., Marcom, P. K., Ellis, M. J., Overmoyer, B. A., Jones, S. F., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.16.584 · Cited by 619
The MRP family of drug efflux pumps
Kruh, G. D., & Belinsky, M. G. (2003) · Oncogene · doi:10.1038/sj.onc.1206953 · Cited by 615
The Role of ABC Transporters in Drug Resistance, Metabolism and Toxicity
Glavinas, H., Krajcsi, P., Cserepes, J., & Sarkadi, B. (2004) · Current Drug Delivery · doi:10.2174/1567201043480036 · Cited by 559
Litman, T., Brangi, M., Hudson, E., Fetsch, P. A., Abati, A. D., Ross, D. D., Miyake, K., Resau, J. H., & Bates, S. E. (2000) · Journal of Cell Science · doi:10.1242/jcs.113.11.2011 · Cited by 538
Multiple Drug Resistance in Cancer Revisited: The Cancer Stem Cell Hypothesis
Donnenberg, V. S., & Donnenberg, A. D. (2005) · The Journal of Clinical Pharmacology · doi:10.1177/0091270005276905 · Cited by 457
Cited by
Sorted by citations
Items 101–200 of 396
Pyrimidine: A promising scaffold for optimization to develop the inhibitors of ABC transporters
He, Z., Zhao, T., Gong, Y., Zhang, X., Ma, L., & Liu, H. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112458 · Cited by 55
Deng, W., Dai, C.-L., CHEN, J.-J., Kathawala, R. J., SUN, Y.-L., CHEN, H.-F., Fu, L., & Chen, Z. (2013) · Oncology Reports · doi:10.3892/or.2013.2362 · Cited by 54
Self-citationShukla, S., Skoumbourdis, A. P., Walsh, M. J., Hartz, A. M. S., Fung, K. L., Wu, C., Gottesman, M. M., Bauer, B., Thomas, C. J., & Ambudkar, S. V. (2011) · Molecular Pharmaceutics · doi:10.1021/mp2001022 · Cited by 54
Self-citationWang, S., Liu, S., Zhao, B., Yang, F., Wang, Y.-T., Liang, Q., Sun, Y., Liu, Y., Song, Z., Cai, Y., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.4536 · Cited by 56
Self-citationZhang, H., Patel, A. S., Ma, S., Li, X. J., Zhang, Y.-K., Yang, P., Kathawala, R. J., Wang, Y., Anreddy, N., Fu, L., et al. (2014) · British Journal of Pharmacology · doi:10.1111/bph.12889 · Cited by 53
Self-citationXiang, Q., Zhang, D., Wang, J., Zhang, H., Zheng, Z., Yu, D., Li, Y., Xu, J. H., Chen, Y., & Shang, C. (2014) · Liver International · doi:10.1111/liv.12524 · Cited by 53
Wang, X.-K., He, J., Xu, J.-H., Ye, S., Wang, F., Zhang, H., Huang, Z.-C., To, K. K. W., & Fu, L. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-3553 · Cited by 53
Self-citationNew Use for an Old Drug: Inhibiting ABCG2 with Sorafenib
Wei, Y., Yuan-fang Ma, A., Zhao, Q., Ren, Z., Li, Y., Hou, T., & Peng, H. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-0215 · Cited by 53
Chen, Z., Chen, Y., Xu, M., Chen, L., Zhang, X., To, K. K. W., Zhao, H., Wang, F., Xia, Z., Chen, X., et al. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0939 · Cited by 53
Self-citationNovel and Alternative Targets Against Breast Cancer Stemness to Combat Chemoresistance
Sridharan, S., Howard, C. M., Tilley, A. M. C., Subramaniyan, B., Tiwari, A. K., Ruch, R. J., & Raman, D. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.01003 · Cited by 54
Self-citationWisinski, K. B., Tevaarwerk, A. J., Burkard, M. E., Rampurwala, M. M., Eickhoff, J. C., Bell, M. C., Kolesar, J., Flynn, C. M., & Liu, G. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2365 · Cited by 52
Exploring naturally occurring ivy nanoparticles as an alternative biomaterial
Huang, Y., Wang, Y., Wang, Y., Yi, S., Fan, Z., Sun, L., Lin, D., Anreddy, N., Hua Zhu, C., Schmidt, M., et al. (2015) · Acta Biomaterialia · doi:10.1016/j.actbio.2015.07.035 · Cited by 52
Self-citationTackling multidrug resistance mediated by efflux transporters in tumor-initiating cells
McIntosh, K., Balch, C., & Tiwari, A. K. (2016) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2016.1179280 · Cited by 55
Self-citationWang, F., Mi, Y., Chen, X.-G., Wu, X.-P., Liu, Z., Chen, S. P., Liang, Y.-J., Cheng, C., To, K. K. W., & Fu, L.-W. (2012) · Molecular Medicine · doi:10.2119/molmed.2011.00444 · Cited by 50
Self-citationGuo, H., Zhang, G.-N., Wang, Y., Zhang, Y., Sodani, K. S., Talele, T. T., Ashby, C. R., & Chen, Z. (2013) · Oncology Reports · doi:10.3892/or.2013.2870 · Cited by 50
Self-citationWu, T., Chen, Z., To, K. K. W., Fang, X., Wang, F., Cheng, B., & Fu, L. (2016) · Biochemical Pharmacology · doi:10.1016/j.bcp.2016.10.015 · Cited by 52
Self-citationLapatinib nano-delivery systems: a promising future for breast cancer treatment
Bonde, G. V., Yadav, S. K., Chauhan, S., Mittal, P., Ajmal, G., Thokala, S., & Mishra, B. (2018) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2018.1449832 · Cited by 50
Özvegy‐Laczka, C., Hegedüs, C., Szakács, G., & Sarkadi, B. (2009) · Current Cancer Drug Targets · doi:10.2174/156800909788166565 · Cited by 50
To, K. K. W., Poon, D. C., Wei, Y., Wang, F., Lin, G., & Fu, L.-W. (2015) · Biochemical Pharmacology · doi:10.1016/j.bcp.2015.06.034 · Cited by 49
Self-citationReversing multidrug resistance by tyrosine kinase inhibitors
He, M., & Wei, M. (2012) · 癌症：英文版 · doi:10.5732/cjc.011.10315 · Cited by 49
Qiu, Q., Liu, B., Cui, J. H., Li, Z., Deng, X., Qiang, H., Li, J., Liao, C., Zhang, B., Shi, W., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01787 · Cited by 49
PD173074, a selective FGFR inhibitor, reverses ABCB1-mediated drug resistance in cancer cells
Patel, A. S., Tiwari, A. K., Chufán, E. E., Sodani, K. S., Anreddy, N., Singh, S., Ambudkar, S. V., Stephani, R. A., & Chen, Z. (2013) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-013-2184-z · Cited by 48
Self-citationWu, C., Hsiao, S.-H., Huang, Y.-H., Hung, L.-C., Yu, Y.-J., Chang, Y., Hung, T., & Wu, Y. (2020) · Cancers · doi:10.3390/cancers12010195 · Cited by 48
Self-citationPerspectives on drug repurposing to overcome cancer multidrug resistance mediated by ABCB1 and ABCG2
Wu, C., Hsiao, S.-H., & Wu, Y. (2023) · Drug Resistance Updates · doi:10.1016/j.drup.2023.101011 · Cited by 47
Self-citationMa, S., Hu, Y.-P., Wang, F., Huang, Z.-C., Chen, Y., Wang, X.-K., & Fu, L. (2014) · Molecular Medicine · doi:10.2119/molmed.2014.00059 · Cited by 47
Self-citationSodani, K. S., Patel, A. S., Anreddy, N., Singh, S., Yang, D., Kathawala, R. J., Kumar, P., Talele, T. T., & Chen, Z. (2014) · Biochemical Pharmacology · doi:10.1016/j.bcp.2014.02.012 · Cited by 47
Self-citationRecent Advances in Boosting EGFR Tyrosine Kinase Inhibitors-Based Cancer Therapy
Pan, Q., Lu, Y., Li, X., Wu, D., Liu, R., Gao, W., Luo, K., He, B., & Pu, Y. (2023) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.2c00792 · Cited by 48
Urothelial carcinomas: a focus on human epidermal receptors signaling.
Grivas, P. D., Day, M. L., & Hussain, M. (2011) · PubMed Central · Cited by 46
Liu, D.-L., Li, Y., Yang, D., Wang, C., Xu, J. H., Yao, N., Zhang, X., Chen, Z., Ye, W., & Zhang, D. (2015) · International Journal of Oncology · doi:10.3892/ijo.2015.2925 · Cited by 46
Self-citationC@PA: Computer-Aided Pattern Analysis to Predict Multitarget ABC Transporter Inhibitors
Namasivayam, V., Silbermann, K., Wiese, M., Pahnke, J., & Stefan, S. M. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c02199 · Cited by 46
Enzyme-Transporter-Mediated Drug Interactions with Small Molecule Tyrosine Kinase Inhibitors
Shao, J., Markowitz, J. S., Bei, D., & An, G. (2014) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.24113 · Cited by 46
Zhang, D., Shu, C., Chen, J.-J., Sodani, K. S., Wang, J., Bhatnagar, J., Lan, P., Ruan, Z., Xiao, Z., Ambudkar, S. V., et al. (2012) · Molecular Pharmaceutics · doi:10.1021/mp300249s · Cited by 46
Self-citationInteraction of Tyrosine Kinase Inhibitors with the MDR-Related ABC Transporter Proteins
Wang, X.-K., & Fu, L. (2010) · Current Drug Metabolism · doi:10.2174/138920010792927316 · Cited by 44
Self-citationLi, F., Danquah, M. K., Singh, S. P., Wu, H., & Mahato, R. I. (2011) · Drug Delivery and Translational Research · doi:10.1007/s13346-011-0042-2 · Cited by 44
Yang, K., Chen, Y., To, K. K. W., Wang, F., Li, D., Chen, L., & Fu, L. (2017) · Experimental & Molecular Medicine · doi:10.1038/emm.2016.168 · Cited by 44
Self-citationYin, H., Dong, J., Cai, Y., Shi, X., Wang, H., Liu, G., Tang, Y., Liu, J., & Ma, L. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.05.053 · Cited by 44
Fallacara, A. L., Zamperini, C., Podolski-Renić, A., Dinić, J., Stanković, T., Stepanović, M., Mancini, A., Rango, E., Iovenitti, G., Molinari, A., et al. (2019) · Cancers · doi:10.3390/cancers11060848 · Cited by 44
Zhou, X., Shi, K., Hao, Y., Yang, C., Zha, R., Cheng, Y., & Qian, Z. (2019) · Asian Journal of Pharmaceutical Sciences · doi:10.1016/j.ajps.2019.06.001 · Cited by 44
Collins, D. M., Crown, J. P., O’Donovan, N., Devery, A., O’Sullivan, F., O’Driscoll, L., CLYNES, M. M., & O'Connor, R. A. (2009) · Investigational New Drugs · doi:10.1007/s10637-009-9266-0 · Cited by 44
Wu, C., Hung, T., Hsiao, S.-H., Huang, Y.-H., Hung, L.-C., Yu, Y.-J., Chang, Y., Wang, S.-P., & Wu, Y. (2020) · Cancers · doi:10.3390/cancers12061366 · Cited by 43
Self-citationInteraction of innovative small molecule drugs used for cancer therapy with drug transporters
Mandery, K., Glaeser, H., & Fromm, M. F. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01618.x · Cited by 42
Perry, J., Ghazaly, E. A., Kitromilidou, C., McGrowder, E. H., Joel, S., & Powles, T. B. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-0197 · Cited by 42
Zhang, H., Patel, A. S., Wang, Y.-J., Zhang, Y.-K., Kathawala, R. J., Qiu, L., Patel, B. A., Huang, L.-H., Shukla, S., Yang, D., et al. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0511 · Cited by 42
Self-citationChen, J., Sun, Y., Tiwari, A. K., Xiao, Z., Sodani, K. S., Yang, D., Vispute, S. G., Jiang, W., Chen, S., & Chen, Z. (2012) · Cancer Science · doi:10.1111/j.1349-7006.2012.02328.x · Cited by 42
Self-citationDamaraju, V. L., Scriver, T., Mowles, D., Kuzma, M., Ryan, A. J., Cass, C. E., & Sawyer, M. B. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2293 · Cited by 42
Saracatinib (AZD0530) is a potent modulator of ABCB1‐mediated multidrug resistancein vitroandin vivo
Liu, K., He, J., Su, X., Sim, H., Xie, J., Chen, X.-G., Wang, F., Liang, Y.-J., Singh, S., Sodani, K. S., et al. (2012) · International Journal of Cancer · doi:10.1002/ijc.27649 · Cited by 41
Self-citationWu, C., Hung, T., Lusvarghi, S., Chu, Y.-H., Hsiao, S.-H., Huang, Y.-H., Chang, Y., & Ambudkar, S. V. (2021) · Biochemical Pharmacology · doi:10.1016/j.bcp.2021.114516 · Cited by 41
Self-citationDrug resistance: from bacteria to cancer
Patel, H. H., Wu, Z., Chen, Y., Bo, L., & Chen, Z. (2021) · Molecular Biomedicine · doi:10.1186/s43556-021-00041-4 · Cited by 43
Self-citationWang, S., Teng, Q., Wang, S., Lei, Z., Hu, H., Lv, H., Chen, B., Wang, J., Shi, X., Xu, W., et al. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.03.023 · Cited by 40
Self-citationKathawala, R. J., Sodani, K. S., Chen, K., Patel, A. S., Abuznait, A. H., Anreddy, N., Sun, Y.-L., Kaddoumi, A., Ashby, C. R., & Chen, Z. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0743 · Cited by 40
Self-citationHu, J., Zhang, X., Wang, F., Wang, X., Yang, K., Xu, M., To, K. K. W., Li, Q., & Fu, L. (2015) · Oncotarget · doi:10.18632/oncotarget.5989 · Cited by 40
Self-citationWen-ji, Z., Li, Y., Wei, M.-N., Chen, Y., Qiu, J.-G., Jiang, Q., Yang, Y., Zheng, D.-W., Qin, W.-M., Huang, J.-R., et al. (2016) · Cancer Letters · doi:10.1016/j.canlet.2016.11.011 · Cited by 40
Self-citationHsiao, S.-H., Lusvarghi, S., Huang, Y.-H., Ambudkar, S. V., Hsu, S., & Wu, C. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.01.001 · Cited by 40
Self-citationTo, K. K. W., Poon, D. C., Wei, Y., Wang, F., Lin, G., & Fu, L. (2015) · British Journal of Pharmacology · doi:10.1111/bph.13189 · Cited by 40
Self-citationWu, C., Hsiao, S.-H., Sim, H., Luo, S.-Y., Tuo, W.-C., Cheng, H.-W., Li, Y., Huang, Y.-H., & Ambudkar, S. V. (2013) · Biochemical Pharmacology · doi:10.1016/j.bcp.2013.08.004 · Cited by 39
Self-citationZhou, Z.-Y., Wan, L.-L., Yang, Q., Han, Y., Li, D., Lu, J., & Guo, C. (2016) · Toxicology Letters · doi:10.1016/j.toxlet.2016.07.710 · Cited by 39
Development of lapatinib nanosponges for enhancing bioavailability
Prabhu, P. P., Prathvi, Gujaran, T. V., Mehta, C. H., Suresh, A., Koteshwara, K. B., Pai, K. G., & Nayak, U. Y. (2021) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2021.102684 · Cited by 39
Gu, X., Ren, Z., Tang, X., Peng, H., Yuan-fang Ma, A., Lai, Y., Peng, S., & Zhang, Y. (2012) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2012.02.050 · Cited by 40
Tao, G., & Chityala, P. K. (2021) · Toxicology Research · doi:10.1093/toxres/tfab026 · Cited by 39
Mansi, M., Howley, R., Chandratre, S., & Chen, B. (2022) · Biochemical Pharmacology · doi:10.1016/j.bcp.2022.115031 · Cited by 38
Ravar, F., Saadat, E., Dehghankelishadi, P., & Dorkoosh, F. A. (2015) · Journal of Liposome Research · doi:10.3109/08982104.2015.1070174 · Cited by 38
Wu, C., Lusvarghi, S., Hsiao, S.-H., Liu, T.-C., Li, Y., Huang, Y.-H., Hung, T., & Ambudkar, S. V. (2020) · Journal of Natural Products · doi:10.1021/acs.jnatprod.9b01022 · Cited by 38
Self-citationShome, R., & Ghosh, S. S. (2021) · Cellular Oncology · doi:10.1007/s13402-020-00576-8 · Cited by 39
Boichuk, S., Дунаев, П. Д., Ганиевич, М. И., Mani, S., Syuzov, K., Валерьевна, В. Е., Bikinieva, F., & Galembikova, A. R. (2022) · Biomedicines · doi:10.3390/biomedicines10030601 · Cited by 38
Cheng, C., Liu, Z.-G., Zhang, H., Xie, J., Chen, X.-G., Zhao, X.-Q., Wang, F., Liang, Y.-J., Chen, L.-K., Singh, S., et al. (2012) · Molecular Pharmaceutics · doi:10.1021/mp2006714 · Cited by 37
Self-citationWu, C., Hsiao, S.-H., Murakami, M., Lin, Y.-J., Li, Y., Huang, Y.-H., Hung, T., Ambudkar, S. V., & Wu, Y. (2017) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.7b00334 · Cited by 37
Self-citationHuman epidermal growth factor receptor targeted inhibitors for the treatment of ovarian cancer
Maria, B., Sims, A. H., & Simon, P. L. (2018) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2018.0062 · Cited by 37
Gao, H., Gupta, P., Cui, Q., Ashar, Y. V., Wu, Z., Zeng, L., Lei, Z., Teng, Q., Ashby, C. R., Guan, Y., et al. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.574861 · Cited by 39
Self-citationVinciguerra, D., Jacobs, M., Denis, S., Mougin, J., Guillaneuf, Y., Lazzari, G., Zhu, C., Mura, S., Couvreur, P., & Nicolas, J. (2019) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.12.047 · Cited by 37
Kathawala, R. J., Wei, L., Anreddy, N., Chen, K., Patel, A. S., Alqahtani, S., Zhang, Y.-K., Wang, Y.-J., Sodani, K. S., Kaddoumi, A., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.2638 · Cited by 35
Self-citationGuo, X., To, K. K. W., Chen, Z., Wang, X., Zhang, J., Luo, M., Wang, F., Yan, S., & Fu, L. (2018) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-018-0690-x · Cited by 35
Self-citationLevit, S. L., Yang, H., & Tang, C. (2020) · Nanomaterials · doi:10.3390/nano10030561 · Cited by 36
Effect of BIBF 1120 on reversal of ABCB1-mediated multidrug resistance
Xiang, Q.-F., Wang, F., Su, X., Liang, Y.-J., Zheng, L.-S., Mi, Y., Chen, W., & Fu, L. (2011) · Cellular Oncology · doi:10.1007/s13402-010-0003-7 · Cited by 36
Self-citationWu, C., Hsiao, S.-H., Su, C.-Y., Luo, S.-Y., Li, Y., Huang, Y.-H., Hsieh, C., & Huang, C. (2014) · Biochemical Pharmacology · doi:10.1016/j.bcp.2014.10.003 · Cited by 35
Self-citationBauer, M., Karch, R., Wulkersdorfer, B., Philippe, C., Nics, L., Klebermass, E., Weber, M., Poschner, S., Haslacher, H., Jäger, W. R., et al. (2018) · Journal of Nuclear Medicine · doi:10.2967/jnumed.118.216432 · Cited by 35
Mechanistic basis of breast cancer resistance protein inhibition by new indeno[1,2-b]indoles
Kita, D. H., Guragossian, N., Zattoni, I. F., Moure, V. R., Rego, F. G. D. M., Lusvarghi, S., Moulenat, T., Belhani, B., Picheth, G., Bouacida, S., et al. (2021) · Scientific Reports · doi:10.1038/s41598-020-79892-w · Cited by 37
Self-citationZhang, H., Wang, Y.-J., Zhang, Y.-K., Wang, D.-S., Kathawala, R. J., Patel, A., Talele, T. T., Chen, Z.-S., & Fu, L.-W. (2014) · Cancer Letters · doi:10.1016/j.canlet.2014.04.008 · Cited by 34
Self-citationTeng, Q., Lei, Z., Wang, J., Yang, Y., Wu, Z., Acharekar, N., Zhang, W., Yoganathan, S., Pan, Y., Wurpel, J. N. D., et al. (2023) · Drug Resistance Updates · doi:10.1016/j.drup.2023.101028 · Cited by 34
Self-citationWu, C., Hsieh, Y., Hsiao, S.-H., Su, C.-Y., Li, Y., Huang, Y.-H., Huang, C., Hsieh, C., Yu, J., & Wu, Y. (2016) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.5b00687 · Cited by 34
Self-citationLapatinib resistance in HER2+ cancers: latest findings and new concepts on molecular mechanisms
Shi, H., Zhang, W., Zhi, Q., & Jiang, M. (2016) · Tumor Biology · doi:10.1007/s13277-016-5467-2 · Cited by 36
Radic-Sarikas, B., Halász, M., Huber, K., Winter, G. E., Tsafou, K. P., Papamarkou, T., Brunak, S., Kölch, W., & Superti‐Furga, G. (2017) · Scientific Reports · doi:10.1038/s41598-017-03129-6 · Cited by 33
Yang, T., Wang, S., Li, H., Zhao, Q., Yan, S., Dong, M., Liu, D., Chen, X., & Li, R. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2019.109663 · Cited by 33
Self-citationLu, H., Chen, T., Wang, Y., He, Y., Pang, Z., & Wang, Y. (2022) · Scientific Reports · doi:10.1038/s41598-022-06677-8 · Cited by 33
He, D., Zhao, X.-Q., Chen, X.-G., Fang, Y., Singh, S., Talele, T. T., Qiu, H., Liang, Y.-J., Wang, X.-K., Zhang, G.-Q., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0054181 · Cited by 33
Self-citationWang, Y., Huang, Y., Anreddy, N., Zhang, G.-N., Zhang, Y., Xie, M., Lin, D., Yang, D., Zhang, M., & Chen, Z. (2015) · Oncotarget · doi:10.18632/oncotarget.6711 · Cited by 33
Self-citationGu, X., Ren, Z., Tang, X., Peng, H., Zhao, Q. J., Lai, Y., Peng, S., & Zhang, Y. (2012) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2012.02.034 · Cited by 32
Zhang, Y., Wu, Z., Yang, Y., Wang, J., Li, J., Sun, Z., Teng, Q., Ashby, C. R., & Yang, D. (2020) · Cancers · doi:10.3390/cancers12113249 · Cited by 32
Self-citationHavaleshko, D. M., Smith, S. C., Cho, H., Cheon, S., Owens, C. R., Lee, J. K., Liotta, L. A., Espina, V. A., Wulfkuhle, J. D., Petricoin, E. F., et al. (2009) · Neoplasia · doi:10.1593/neo.09898 · Cited by 32
Temozolomide reverses doxorubicin resistance by inhibiting P-glycoprotein in malignant glioma cells
Zhang, R., Saito, R., Shibahara, I., Sugiyama, S., Kanamori, M., Sonoda, Y., & Tominaga, T. (2015) · Journal of Neuro-Oncology · doi:10.1007/s11060-015-1968-x · Cited by 32
Wu, C., Hsieh, C., Hsiao, S.-H., Luo, S.-Y., Su, C.-Y., Li, Y., Huang, Y.-H., Huang, C., & Hsu, S.-C. (2015) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.5b00312 · Cited by 31
Self-citationNFE2L2/NRF2 silencing-inducible miR-206 targets c-MET/EGFR and suppresses BCRP/ABCG2 in cancer cells
Choi, B.-H., Ryu, D. Y., Ryoo, I.-G., & Kwak, M. (2017) · Oncotarget · doi:10.18632/oncotarget.22513 · Cited by 32
Minami, T., Kijima, T., Otani, Y., Kohmo, S., Takahashi, R., Nagatomo, I., Hirata, H., Suzuki, M., Inoue, K., Takeda, Y., et al. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0884 · Cited by 30
The Multidrug Resistance-Reversing Activity of a Novel Antimicrobial Peptide
Teng, Q., Luo, X., Lei, Z., Wang, J., Wurpel, J. N. D., Qin, Z., & Yang, D. (2020) · Cancers · doi:10.3390/cancers12071963 · Cited by 31
Namasivayam, V., Silbermann, K., Pahnke, J., Wiese, M., & Stefan, S. M. (2021) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2021.05.018 · Cited by 30
Fan, Y., Tao, T., Guo, Z., To, K. K. W., Chen, D., Wu, S., Yang, C., Li, J.-S., Luo, M., Wang, F., et al. (2022) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2022.02.006 · Cited by 30
Self-citationThe AKT inhibitor, MK-2206, attenuates ABCG2-mediated drug resistance in lung and colon cancer cells
Gao, H.-L., Cui, Q.-B., Wang, J.-Q., Ashby, C., Chen, Y.-C., Shen, Z.-R., & Chen, Z.-S. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1235285 · Cited by 29
Self-citationDeterminants of the activity and substrate recognition of breast cancer resistance protein (ABCG2)
Szafraniec, M., Szczygieł, M., Urbańska, K., & Fiedor, L. (2014) · Drug Metabolism Reviews · doi:10.3109/03602532.2014.942037 · Cited by 30
Wei, Y., Xu, S., Wang, F., Zou, A., Zhang, S., Xiong, Y., Cao, S., Zhang, Q., Wang, Y., & Jiang, X. (2014) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.24234 · Cited by 30
Albadari, N. G., Xie, Y., & Li, W. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1340401 · Cited by 30
Tivozanib reverses multidrug resistance mediated by ABCB1 (P-glycoprotein) and ABCG2 (BCRP)
Yang, D., Kathawala, R. J., Chufán, E. E., Patel, A. S., Ambudkar, S. V., Chen, Z., & Chen, X. '. (2013) · Future Oncology · doi:10.2217/fon.13.253 · Cited by 29
Self-citation
Metadata
- Authors
- Dai, C.-L., Tiwari, A. K., Wu, C.-P., Su, X.-D., Wang, S.-R., Liu, D.-G., Ashby, C. R., Huang, Y., Robey, R. W., Liang, Y.-J., Chen, L.-M., Shi, C.-J., Ambudkar, S. V., Chen, Z.-S., & Fu, L.-W.
- Affiliations
- Sun Yat-sen University (CN)
- St. John's University (US)
- National Institutes of Health (US)
- 1State Key Laboratory for Oncology in South China, Cancer Center, Sun Yat-Sen University, Guangzhou, China;
- ORCID
- Venue
- Cancer Research
- Published
- 2008-09-30
- Volume
- 68
- Issue
- 19
- Pages
- 7905-7914
- ISSN
- 0008-5472 (ISSN-L)
- 1538-7445
- PMC
- PMC2652245
- OpenAlex
- W2098064809
- Cited by
- 386
- References
- 54
- Citations by year
- 2026: 6 · 2025: 8 · 2024: 10 · 2023: 11 · 2022: 22 · 2021: 17 · 2020: 32 · 2019: 26 · 2018: 20 · 2017: 23 · 2016: 22 · 2015: 26 · 2014: 43 · 2013: 16 · 2012: 38
- FWCI
- 11.43
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Cancer Research (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- St. John's University (579-1110)
- Sun Yat-sen University
- National Institutes of Health
- National Cancer Institute (Z01BC010030, Z01BC010622)
- Topics
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Health Sciences › Medicine › Microbiology (medical) › Antibiotic Resistance in Bacteria
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- Keywords
- lapatinib, multidrug resistance reversal, P-glycoprotein, ABCG2, ABC transporters, drug efflux, doxorubicin accumulation, methotrexate transport, paclitaxel, tyrosine kinase inhibitors, combination chemotherapy
- MeSH terms
- ATP Binding Cassette Transporter, Subfamily G, Member 2, Lapatinib, Adenosine Triphosphatases, Animals, Antineoplastic Combined Chemotherapy Protocols, Cells, Cultured, Dose-Response Relationship, Drug, Humans, Mice, Nude, Neoplasm Proteins, Neoplasms, Quinazolines, Transfection, Up-Regulation, Gene Expression Regulation, Neoplastic, Paclitaxel, Drug Resistance, Multiple, ATP Binding Cassette Transporter, Subfamily B, ATP-Binding Cassette Transporters, Drug Resistance, Neoplasm, ATP Binding Cassette Transporter, Subfamily B, Member 1, Xenograft Model Antitumor Assays, Tumor Burden, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
